• SELECT SITE CURRENCY
Select a currency for use throughout the site
How Can Industry Build Relationships With Patient Groups?
PatientView, July 2011, Pages: 480
This report provides unique insights from 850 international, national and large regional patient organisations that represent the interests of patients from 11 countries/regions of the world. A full profile of the views of 138 of the groups is also provided.
What the report tells you:
The current state of relationships between industry and patient groups: Patient groups detail the size, scale, and nature of their current relationships with industry (including pharma, medical devices, commercial health insurers, commercial health providers, and consumer health companies).
Which companies work with which patient groups (and what the groups think of the companies): Named groups describe the state of their current relationships with their named industry partners. They mention the companies that they think excel in relationships with patient groups.
The impact of guidelines and regulations on industry/patient-group partnerships: The report ranks the various regulations that govern industry/patient-group partnerships for effect upon those partnerships.
The report provides strategic pointers—both to industry and to patient groups—as to how these relationships can be improved (from the patient group perspective). Patient groups identify the main barriers to forming partnerships. They point out which sources of information help them frame their views about companies—and, what, in their eyes, characterises a company as reputable or not.
This March-May 2011 global survey of 850 international, national and (large) regional patient groups has generated some simple but potent ‘take-home’ messages about industry and patient-group relationships. If implemented by industry, the advice from the respondent patient groups could help increase the effectiveness of the partnerships for patient groups and companies alike.
Foreword by Mat Phillips
What this report tells you
Appendix I: Comparing the results geographically
Appendix II: Results amalgamated
Appendix III: Results from individual countries/regions of the world
[includes mapping of 139 of the patient group respondents]
Belgium, France, Luxembourg
Central and South America
Australasia (Australia and New Zealand); Benelux countries (Belgium, France, Luxembourg and Netherlands); Canada; Central and South America (Argentina, Bolivia, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Peru, Uruguay, and Venezuela); Eastern Europe (Albania, Bulgaria, Croatia, Estonia, Hungary, Kosovo, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine); Germany; Italy; Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden); UK; USA.